Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF 93 Equity-to-Asset is 0.81 as of Jun. 2026, which is 4% below its 10-year median of 0.84. GuruFocus rates KYKOF with a GF Score™ of 93/100 and a GF Value™ of $12.29. The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 81.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kyowa Kirin Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $5,699 Mil. Kyowa Kirin Co's Total Assets for the quarter that ended in Jun. 2026 was $7,035 Mil.
The historical rank and industry rank for Kyowa Kirin Co's Equity-to-Asset or its related term are showing as below:
KYKOF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79 Med: 0.84 Max: 0.88
Current: 0.81
During the past 13 years, the highest Equity to Asset Ratio of Kyowa Kirin Co was 0.88. The lowest was 0.79. And the median was 0.84.
KYKOF's Equity-to-Asset is ranked better than 81.51% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs KYKOF: 0.81
Kyowa Kirin Co (OTCPK:KYKOF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kyowa Kirin Co Equity-to-Asset Related Terms
Kyowa Kirin Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kyowa Kirin Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a Equity-to-Asset of 0.81 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kyowa Kirin Co and its competitors. This is near median its historical median of 0.84. Over the past decade, Kyowa Kirin Co's Equity-to-Asset has ranged from 0.79 to 0.88. According to the industry distribution chart, Kyowa Kirin Co ranks #186 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 18.5%.
Is Kyowa Kirin Co's Equity-to-Asset too high?
Kyowa Kirin Co's current Equity-to-Asset of 0.81 is near median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 0.88. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Kyowa Kirin Co's value of 0.81 is 32.8% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #186 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #186 out of 1006 companies for Equity-to-Asset. This places Kyowa Kirin Co in the top 19% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Kyowa Kirin Co's value of 0.81 is 32.8% above this benchmark. Historically, Kyowa Kirin Co's own Equity-to-Asset has ranged from 0.79 to 0.88 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.61, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Equity-to-Asset of 0.81 is 32.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Equity-to-Asset is 0.81, which is near median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Kyowa Kirin Co (KYKOF) has a current Equity-to-Asset of 0.81. The stock's GF Value™ is $12.29, compared to a current price of $14.43 — trading 17.4% above its estimated fair value. The current Equity-to-Asset is 0.81, which is near median its 10-year median of 0.84 and 32.8% above the Drug Manufacturers industry median of 0.61. Kyowa Kirin Co's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Equity-to-Asset is 0.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be overvalued.
The current stock price of $14.43 is trading 17.4% above its estimated GF Value™ of $12.29.
Key valuation signals for KYKOF:
Equity-to-Asset: 0.81 (near median its 10-year median of 0.84)
GF Value™: $12.29 vs. price of $14.43 (17.4% above fair value)
Industry Position: 32.8% above the Drug Manufacturers median (#186 of 1006)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
93GF Score
Get the complete analysis for KYKOF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
